4D pharma appoints John Doyle as Chief Financial Officer
January 03 2022 - 6:00AM
Business Wire
4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical
company leading the development of Live Biotherapeutic products
(LBPs), a novel class of drug derived from the microbiome, today
announces the appointment of John Doyle as Chief Financial Officer
(CFO). Mr. Doyle brings over 15 years of experience leading and
developing the financial operations, strategy and investor
relations functions at public healthcare companies.
“We are delighted to welcome John to 4D pharma at this exciting
stage of the company’s growth, following our NASDAQ listing in
2021,” said Duncan Peyton, Chief Executive Officer of 4D pharma.
“John’s extensive financial experience in diverse healthcare
organizations and transformational events will be invaluable as 4D
pharma continues to make progress in the clinic on multiple fronts
with our Live Biotherapeutic programs.”
“I am honored to join a company that is committed to delivering
a revolutionary class of medicines by harnessing bacteria from the
microbiome,” said John Doyle, Chief Financial Officer of 4D pharma.
“The 4D pharma team has built an impressive pipeline across key
areas of high unmet need and I am excited for the opportunity to
execute on the company’s growth strategy and financial goals.”
Mr. Doyle joins 4D pharma after serving as CFO at Chiasma Inc.,
a publicly traded biopharmaceutical company acquired by Amryt
Pharma in 2021. Prior to Chiasma, John was Vice President of
Finance and Investor Relations at Verastem Inc., a publicly traded
biopharmaceutical company. Prior to joining Verastem in February
2018, he served as Head of Financial Planning & Analysis at
SimpliVity Corp., a software company that was acquired by Hewlett
Packard Enterprises in February 2017. Before that, Mr. Doyle was
Director of Business Unit Financial Planning & Analysis, Early
Phase Division, at PAREXEL, a publicly traded pharmaceutical
contract research organization. Earlier in his career, he served in
increasingly senior financial planning and analysis roles at
Hologic, Inc., a publicly traded provider of medical diagnostic,
surgical and imaging products. Mr. Doyle holds a B.S. in finance
from the University of Massachusetts.
About 4D pharma
4D pharma is a world leader in the development of Live
Biotherapeutics, a novel and emerging class of drugs, defined by
the FDA as biological products that contain a live organism, such
as a bacterium, that is applicable to the prevention, treatment or
cure of a disease. 4D has developed a proprietary platform,
MicroRx®, that rationally identifies Live Biotherapeutics based on
a deep understanding of function and mechanism.
4D pharma's Live Biotherapeutic products (LBPs) are orally
delivered single strains of bacteria that are naturally found in
the healthy human gut. The Company has five clinical programs,
namely a Phase I/II study of MRx0518 in combination with KEYTRUDA®
(pembrolizumab) in solid tumors, a Phase I study of MRx0518 in a
neoadjuvant setting for patients with solid tumors, a Phase I study
of MRx0518 in patients with pancreatic cancer, a Phase I/II study
of MRx-4DP0004 in asthma, and Blautix® in Irritable Bowel Syndrome
(IBS) which has completed a successful Phase II trial.
Preclinical-stage programs include candidates for CNS disease such
as Parkinson's disease and other neurodegenerative conditions. The
Company has a research collaboration with MSD, a tradename of Merck
& Co., Inc., Kenilworth, NJ, USA, to discover and develop Live
Biotherapeutics for vaccines.
For more information, refer to https://www.4dpharmaplc.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220103005054/en/
4D pharma Investor Relations: ir@4dpharmaplc.com
Singer Capital Markets - Nominated Adviser and Joint Broker +44
(0)20 7496 3000 Philip Davies / James Fischer (Corporate Finance)
Tom Salvesen (Corporate Broking)
Bryan Garnier & Co. Limited - Joint Broker +44 (0)20 7332
2500 Dominic Wilson
Stern Investor Relations, Inc. +1-212-362-1200 Julie Seidel
Julie.seidel@sternir.com
Image Box Communications +44 (0)20 8943 4685 Neil Hunter /
Michelle Boxall neil@ibcomms.agency / michelle@ibcomms.agency
6 Degrees Lynne Dardanell +1-336-202-9689
ldardanell@6degreespr.com
4d Pharma (LSE:DDDD)
Historical Stock Chart
From Mar 2024 to Apr 2024
4d Pharma (LSE:DDDD)
Historical Stock Chart
From Apr 2023 to Apr 2024